New long-term organ damage analysis published for GSK’s Benlysta® (belimumab)

Source: GSK

GSK today announced publication of a new long-term analysis showing that patients with moderate-to-severe systemic lupus erythematosus (SLE) treated with Benlysta (belimumab) plus standard of care (SoC) over five years experienced low rates of organ damage progression, regardless of their baseline level of damage.
 

Benlysta was the first medicine specifically developed and approved for SLE in over 50 years when its regulatory licence was granted in 2011. It is a human monoclonal antibody that selectively targets B-lymphocyte stimulator (BLyS), an important factor in the survival of B cells.

Results of the analysis are available at http://lup.sagepub.com/content/early/2016/02/18/0961203315625119.full.pdf+html